PAncreatic Disease Cohort of TOuLouse
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Pancreatic Diseases. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study is a prospective cohort dedicated to pancreatic diseases excluding cancer. The aim is to develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies. During this study the investigators collect data and biological samples to support research project.
Detailed description
This collection focuses on pathology of the pancreas requiring specific investigations or management for diagnosis or treatment. Pancreatic pathologies can be classified as malignant, potentially malignant or benign tumors. These can be solid or cystic. There is an inflammatory attack on the pancreas, generating acute pancreatitis in the acute period, if the inflammatory manifestations persist, chronic pancreatitis will develop. Some lesions may be at risk of malignancy during their evolution, it is therefore necessary to improve the performance of monitoring and diagnostic tools in order to adapt the management of patients.
Primary outcome measures
- Diagnostic tools [Time frame: 3 years after the first inclusion]
Secondary outcome measures (4)
- New targets [Time frame: 3 years after the first inclusion]
- Improvement of management [Time frame: 3 years after the first inclusion]
- Microbiota [Time frame: 3 years after the first inclusion]
- Clinical data access [Time frame: 3 years after the first inclusion]
Eligibility criteria
Inclusion criteria
- Patients with inflammatory or cystic exocrine pancreatic pathology
- Patient able to read and understand the information leaflet
- Patients who have agreed to participate in the study and have signed the free and informed consent
- Patients affiliated to a social security system (including AME)
Exclusion criteria
- Patient with pancreatic cancer pathology
- Patients with active cancer, whatever the origin
- Pregnant or breastfeeding patients
- Patients under legal protection, guardianship or trusteeship
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- Rangueil hospital — Toulouse
Publications
- Bardol T, Dujon AM, Taly V, Dunyach-Remy C, Lavigne JP, Costa-Silva B, Kurma K, Eslami-S Z, Cayrefourcq L, Canivet C, Muscari F, Bournet B, Alix-Panabieres C. Early detection of pancreatic cancer by liquid biopsy "PANLIPSY": a french nation-wide study project. BMC Cancer. 2024 Jun 10;24(1):709. doi: 10.1186/s12885-024-12463-8. PMID 38853244
Identifiers
NCT: NCT05824403 · RC31/22/0530